2019 novel coronavirus infection
Conditions
Interventions
Study Group:Symptomatic treatment+lamivudine 10mg qd*5 days
Control group:Symptomatic treatment+azvudine 5mg qd*5 days
Sponsors
Emergency Department of Rongxian People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. Patients who met the diagnostic criteria for COVID-19 (Trial Version 10) and were within 24 hours of onset, or were nucleic acid positive and asymptomatic.
Exclusion criteria
Exclusion criteria: 1. Known or suspected hypersensitivity to components of lamivudine; 2. Pregnant or lactating women; 3. Participated in other clinical trials or taking experimental drugs within 12 weeks before administration; 4. Other anti-COVID-19 drugs such as Paxlovid, monoravir, azifudine, or ursodeoxycholic acid were taken within 1 week before administration; 5. According to the judgment of the investigator, there are other conditions that are not suitable for participating in this trial; 6. Refuse to be enrolled or give up treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of clinical sign and symptom: including the duration of symptoms such as fever, general pain (or soreness), sore throat, nasal congestion, loss of taste or (and) smell;Incidence of characteristic pneumonia manifestations of novel coronavirus infection on pulmonary imaging;Incidence of Moderate, Severe, and Critical;Patient prognosis; | — |
Countries
China
Contacts
Public ContactYu Wang
Rongxian People's Hospital
Outcome results
None listed